Elucidation of the mechanism how Vandetanib kills RET-positive lung cancer cells

2015 Fiscal Year Final Research Report

• Project/Area Number: 26830121
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Tumor therapeutics
• Research Institution: National Cancer Center Japan
• Principal Investigator: Makinoshima Hideki 国立研究開発法人国立がん研究センター, 先端医療開発センター, 研究員 (30510573)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: 融合遺伝子

Outline of Final Research Achievements

Rearrangements of the proto-oncogene RET were newly identified potential driver mutations in lung adenocarcinoma. We had found the cell line LC2/ad harboring RET fusion gene and Vandetanib was the most effective compound to inhibit LC2/ad cells by down-regulating RET fusion protein. To elucidate the mechanism how Vandetanib efficiently kills RET-positive lung cancer cells, we have identified Vandetanib-target molecules in addition to RET and established Vandetanib-resistant cell lines.

Free Research Field

腫瘍治療学